ASR Vermogensbeheer’s Neurocrine Biosciences NBIX Stock Holding History

ASR Vermogensbeheer’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$979K	Buy	5,808 +1,598	+38%	+$237K	0.01%	410
2026 Q1	$555K	Buy	4,210 +75	+2%	+$9.95K	0.01%	471
2025 Q4	$586K	Sell	4,135 -37	-0.9%	-$5.36K	0.01%	469
2025 Q3	$586K	Sell	4,172 -20	-0.5%	-$2.71K	0.01%	475
2025 Q2	$527K	Sell	4,192 -16	-0.4%	-$1.83K	0.01%	484
2025 Q1	$465K	Buy	+4,208	New	+$533K	0.01%	493

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ASR Vermogensbeheer's NBIX Position: Q2 2026 in Review

ASR Vermogensbeheer increased its Neurocrine Biosciences (NBIX) stake by 38% in Q2 2026, buying an estimated $237K and bringing the position to 5,808 shares worth $979K. The position accounts for 0.01% of the portfolio, ranked #410.

ASR Vermogensbeheer first reported a position in NBIX in Q1 2025 and has held it in 6 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

ASR Vermogensbeheer held 5,808 shares of Neurocrine Biosciences worth $979K as of Q2 2026.
ASR Vermogensbeheer bought 1,598 Neurocrine Biosciences shares in Q2 2026, an estimated $237K.
Neurocrine Biosciences made up 0.01% of ASR Vermogensbeheer's portfolio in Q2 2026, its #410 holding.
ASR Vermogensbeheer first reported a position in Neurocrine Biosciences in Q1 2025 and has held it in 6 quarters since.
772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on ASR Vermogensbeheer's 13F filing for Q2 2026, filed 20 Jul 2026.